论文部分内容阅读
上海抗癌药物咨询中心组成由上海市10个临床综合性医院参加的抗癌药物临床观察组,于1991年1月至10月先后随机选择应用鮀滨—华明阿霉素为主,联合化疗方案治疗恶性肿瘤患者174例,作近期疗效和毒性反应观察,临床报告如下: 一、资料分析 174例中晚期恶性肿瘤患者,其中161例有手术病理或脱落细胞检查阳性;13例根据胸片、B超、CT诊断,体检能触及癌性肿块,或有明显转移病灶,癌性胸腹水,消化道梗阻等并发症。包括已失去手术机会的晚期肿瘤患者及术后复发病例。男性114例,女性60例,男∶女=1.9∶1年龄在34～80岁之间,平均年龄59.9岁。其
The Shanghai Anti-cancer Drugs Consultation Center formed a clinical observation group for cancer drugs participated by 10 clinical general hospitals in Shanghai. From January to October 1991, they randomly selected Sibanbin-Huamin Adriamycin as the mainstay of combination chemotherapy. The protocol treats 174 patients with malignant tumors for short-term efficacy and toxicity observations. Clinical reports are as follows: 1. Data analysis of 174 patients with advanced and advanced malignant tumors, of which 161 patients had positive surgical or pathological examinations; 13 patients were diagnosed according to chest radiographs. B-ultrasound, CT diagnosis, physical examination can reach cancerous masses, or there are obvious metastatic lesions, cancerous pleural effusion, digestive tract obstruction and other complications. Including advanced cancer patients who have lost surgery and postoperative recurrences. There were 114 males and 60 females. The male and female = 1.9:1 were between 34 and 80 years old, and the average age was 59.9. its